Receptor-interacting protein kinase-1 ablation in liver parenchymal cells promotes liver fibrosis in murine NASH without affecting other symptoms
Authors:
- Muhammad FarooqMuhammad Farooq
- Mélanie Simoes EugénioMEMélanie Simoes Eugénio
- Claire Piquet-PellorceCPClaire Piquet-Pellorce
- Sarah DionSDSarah Dion
- Céline Raguenes-NicolCRCéline Raguenes-Nicol
- Kathleen SantamariaKSKathleen Santamaria
- Ghania Hounana Kara-AliGKGhania Hounana Kara-Ali
- Marie-Thérèse Dimanche-BoitrelMarie-Thérèse Dimanche-Boitrel
- Michel SamsonMSMichel Samson
- Jacques Le SeyecJSJacques Le Seyec
- 27 April 2022
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 100 (7) , 1027-1038
Abstract
Non-alcoholic steatohepatitis (NASH), a chronic liver disease that emerged in industrialized countries, can further progress into liver fibrosis, cirrhosis, and hepatocellular carcinoma. In the next decade, NASH is predicted to become the leading cause of liver transplantation, the only current interventional therapeutic option. Hepatocyte death, triggered by different death ligands, plays key role in its progression. Previously, we showed that the receptor-interacting protein kinase-1 (RIPK1) in hepatocytes exhibits a protective role in ligand-induced death. Now, to decipher the role of RIPK1 in NASH, Ripk1LPC−KO mice, deficient for RIPK1 only in liver parenchymal cells, and their wild-type littermates (Ripk1fl/fl) were fed for 3, 5, or 12 weeks with high-fat high-cholesterol diet (HFHCD). The main clinical signs of NASH were analyzed to compare the pathophysiological state established in mice. Most of the symptoms evolved similarly whatever the genotype, whether it was the increase in liver to body weight ratio, the steatosis grade or the worsening of liver damage revealed by serum transaminase levels. In parallel, inflammation markers followed the same kinetics with significant equivalent inductions of cytokines (hepatic mRNA levels and blood cytokine concentrations) and a main peak of hepatic infiltration of immune cells at 3 weeks of HFHCD. Despite this identical inflammatory response, more hepatic fibrosis was significantly evidenced at week 12 in Ripk1LPC−KO mice. This coincided with over-induced rates of transcripts of genes implied in fibrosis development (Tgfb1, Tgfbi, Timp1, and Timp2) in Ripk1LPC−KO animals. In conclusion, our results show that RIPK1 in hepatocyte limits the progression of liver fibrosis during NASH.Keywords
This publication has 52 references indexed in Scilit:
- Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease modelsCell Death & Disease, 2012
- Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitisJournal of Hepatology, 2012
- Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitisWorld Journal of Gastroenterology, 2012
- Invariant natural killer T‐cell‐deficient mice display increased CCl4‐induced hepatitis associated with CXCL1 over‐expression and neutrophil infiltrationEuropean Journal of Immunology, 2011
- Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver diseaseJournal of Lipid Research, 2010
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†Hepatology, 2009
- Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- Liver nbsp fibrosis signals leading to the amplification of the fibrogenic hepatic stellate cellFrontiers in Bioscience-Landmark, 2003
- TNF-Dependent Recruitment of the Protein Kinase RIP to the TNF Receptor-1 Signaling ComplexImmunity, 1996
- RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell deathCell, 1995